The National Cancer Institute (NCI) awarded a $415,260 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Methodist Hospital Research Institute in Houston, Texas to explore a novel combinatorial approach integrating chimeric antigen receptor (CAR)-T cell therapy with targeted radiotherapy (TRT) for enhancing cancer immunotherapy. The research aims to: 1) investigate the impact of image-guided TRT using the FDA-approved theranostic agent 177Lu-DOTATATE on anti-tumor immune responses, and 2) elucidate the underlying mechanisms behind the synergistic effects of combining TRT with CAR-T cell therapy. The project, which runs from June 1, 2024 to May 31, 2026, seeks to address key limitations of CAR-T cell therapy in solid tumors and advance this innovative combination approach to improve cancer treatment outcomes.
Generated 3/4/25, 2:45 AM